|
 |
| home > ebr > winter 2002 > cell-based high-throughput screens for drug discovery |
 |
 |
PUBLICATIONS |
European BioPharmaceutical Review
|
The rapid progress in elucidating the mechanisms underlying human diseases, along with the enormous amount of data generated by the Human Genome Project, are significantly increasing the number of proteins that can be targeted for potential drug treatment. Parallel to these developments, the number and diversity of compounds that can be tested for activity against these targets are also rapidly expanding.
The combination of these trends in biology and chemistry has spurred the development of increasingly rapid, selective and reliable high-throughput screening assays to be applied in the early phase of drug discovery Typically, such assays allow screening of large numbers of compounds in an automated fashion to identify those that show an activity, either as agonists or as antagonists, on a defined biological target. Most of the assay formats developed to date can be grouped into cell-free (biochemical) or cell-based (cellular) assays. This article describes the applicability of cell-based assays in the early phase of drug discovery, with a particular focus on the use of yeast cells as an attractive option for high-throughput screens.
|
Read full article >>
|
 |
 |
 |
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
 |

 |
Industry Events |
 |
FT Global Pharmaceutical and Biotechnology Conference 2008
2-3 December 2008, The Cumberland, London
FT Global Pharmaceutical and Biotechnology Conference is Europe’s pre-eminent industry event attended by leading executives, government decision makers, investors, analysts and other specialist providers. It provides a unique platform to present new perspectives,’ feel the pulse’ of the industry, and network with peers across the sector.
More info >> |
|
 |
News and Press Releases |
 |
Financial Times hosts the Global Pharmaceutical and Biotechnology Conference
13th November 2008
More info >> |
|
|